Fundamentals and Advances in Immunotherapy in the Oncology Patient 2024
Fundamentals and Advances in Immunotherapy in the Oncology Patient 2024
Regular price
$40.00 USD
Regular price
$40.00 USD
Sale price
Unit price
per
Couldn't load pickup availability
Fundamentals and Advances in Immunotherapy in the Oncology Patient 2024
Regular price
$40.00
Regular price
$40.00
Sale price
Unit price
per
Fundamentals and Advances in Immunotherapy in the Oncology Patient 2024
Immunotherapy in the Oncology Patient
- Include: 23 videos + 1 pdf, size: 5.44 GB
- Target Audience: physicians, and nurses who care for oncology patient
- Sample video: contact me for sample video
Date & Location
Wednesday, January 24, 2024, 8:00 AM – 5:20 PM, Online, New York , NY
Specialties
Specialties – Allergy and Immunology, Bone Marrow Transplant, Breast Medical Oncology, Cellular Therapeutics, Critical Care, Dermatology, Endocrinology, Diabetes and Metabolism, Gastrointestinal Oncology, Genitourinary Oncology, Gynecologic Oncology, Head and Neck Oncology, Hepatology, Hospice and Palliative Medicine, Immunotherapy, Leukemia, Lymphoma, Medical Oncology, Neurology, Neuro-Oncology, Nurse Practitioner, Nursing, Oncology and Hematology, Pharmacology and Medication Management, Physician Assistant, Pulmonary Medicine, Radiation Oncology, Rheumatology, Solid Tumor Oncology
Overview
Immunotherapy in the Oncology Patient
Immunotherapeutics has changed the landscape of treatment modalities available to the cancer patient in both solid tumor and hematologic malignancies. Since the breakthrough of ipilimumab, there have been fast-paced and ongoing advancements in the field of immunotherapy, revolutionizing clinical management at a rapid pace.
This one-day virtual symposium will review fundamental concepts and recent advances in immunotherapy designed to meet the learning needs of advanced practice providers (APPs) and other allied health professionals. Clinical application in solid tumor and hematologic malignancies will be discussed as well as toxicity management, including immune-related adverse events resulting from immune checkpoint inhibition.
Experts will discuss the fundamentals of immune checkpoint blockade and CAR T cell therapy, as well as advancements in TIL and BITE therapy, novel combination therapy, and algorithmic management of immune-related adverse events. Toxicity management will be communicated through case study applications and demonstration of common, rare, and severe immune-related adverse events.
The overall goal of this program is to improve cancer patient outcomes by advancing the science, development, and application of cancer immunology and immunotherapy through fundamental understanding and clinical application.
Attendees of this symposium will receive access to an online syllabus, which includes select video recordings of the lectures.
Target Audience
The target audience for this course includes nurse practitioners, physician assistants, certified registered nurse anesthetists, physicians, and nurses who care for oncology patient.
Objectives
At the conclusion of this symposium, learners will be able to:
- Describe the principles surrounding the immunity cycle
- Explain fundamental principles of immunotherapeutic agents including immune checkpoint inhibition, CAR T cell, TIL, and BITE therapies.
- Discuss the symptoms of Cytokine release Syndrome, ICANS, prolonged cytopenias and clinical management
- Recognize and identify common, rare, and severe immune related adverse events attributed to immune checkpoint inhibition
- Discuss clinical application of immune modulated agents in the oncology population
Topics:
- APPImmuno2024_Brochure.pdf
- Arthralgias and Myalgias.mp4
- Benefit of Adjuvant Combination Therapy vs. Surveillance in High Risk Hepatocellular Carcinoma Patients.mp4
- Clinical Landscape of Immunotherapy in Soft Tissue Sarcoma- Fundamentals and Advances in Immunotherapy.mp4
- Dermatologic irAEs.mp4
- FDA Approved CAR T Products in the Treatment and Management of Leukemia.mp4
- Fundamentals of Chimeric Antigen Receptor (CAR) T Cell Immunotherapy.mp4
- Hepatotoxicty.mp4
- Immunotherapy and CAR T Cell Therapy in Hematologic Malignancies Lymphoma.mp4
- Immunotherapy Induced Diabletes Mellitus.mp4
- Implementation of Cellular Therapy in the Solid Tumor Population- The Use of TIL Therapy in Melanoma.mp4
- Mechanism of Action of Checkpoint Blockade With a Focus on PD1, PDL1, and CTLA-4.mp4
- Neoadjuvant Combination Modalites in Resectable Non Small Cell Lung Cancer.mp4
- Novel Checkpoint Inhibitors and Combination Therapy in the Clinical Setting.mp4
- Novel Immune Modulated Agents in the Treatment of Glioblastoma.mp4
- Overall Survival (OS) in Recurrent or Metastatic Cervical Cancer Using Combination Therapy.mp4
- Overview of Adverse Events in the Cellular Therapy Patient- CRS, ICANS, and Prolonged Cytopenias.mp4
- Panel Discussion- Clinical Application of Immune Checkpoint Inhibitors in Solid Tumor Malignancy.mp4
- Panel Discussion- Clinical Application of Immune Therapy in Hematologic Malignancy.mp4
- Panel Discussion- Clinical Updates in Solid Tumor and Novel Immune Modulation.mp4
- Panel Discussion- Diagnosis and Clinical Management of Immune Related Adverse Events (irAE).mp4
- Panel Discussion- Fundamentals of T Cell Therapy.mp4
- Pneumonitis.mp4
- T Cell Re-Directing Therapy in Multiple Myeloma.mp4
